Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China.
School of Pharmacy, Institute of Liver Diseases, Anhui Medical University, Hefei 230032, Anhui, China.
Int J Biol Sci. 2020 Oct 17;16(16):3174-3183. doi: 10.7150/ijbs.49535. eCollection 2020.
Alcoholic liver disease (ALD) is the most prevalent type of chronic liver disease worldwide with a wide spectrum of liver pathologies ranging from simple steatosis to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. It has been demonstrated that ALD is mediated in whole or in part by a central signaling molecule sirtuin 1 (SIRT1), a conserved class III histone deacetylase.SIRT1 plays beneficial roles in regulating hepatic lipid metabolism, inhibiting hepatic inflammation, controlling hepatic fibrosis and mediating hepatocellular carcinoma in ALD. However, underlying molecular mechanisms are complex and remain incompletely understood. The aim of this review was to highlight the latest advances in understanding of SIRT1 regulatory mechanisms in ALD and discuss their unique potential role as novel therapeutic target for ALD treatment.
酒精性肝病(ALD)是全球最常见的慢性肝病,其肝脏病理变化广泛,从单纯性脂肪变性到脂肪性肝炎、肝硬化,甚至肝细胞癌。已经证明,ALD 是由一种中央信号分子沉默调节蛋白 1(SIRT1)介导的,它是一种保守的 III 类组蛋白去乙酰化酶。SIRT1 在调节肝脏脂质代谢、抑制肝脏炎症、控制肝纤维化和介导 ALD 中的肝细胞癌方面发挥有益作用。然而,潜在的分子机制很复杂,仍不完全清楚。本综述的目的是强调 SIRT1 在 ALD 中的调节机制的最新研究进展,并讨论其作为 ALD 治疗的新型治疗靶点的独特潜力。
Int J Biol Sci. 2020
Int J Biol Sci. 2017-7-6
World J Gastroenterol. 2014-7-7
Gastroenterology. 2013-11-18
Hepatobiliary Surg Nutr. 2015-4
Curr Mol Pharmacol. 2017
Cell Biochem Funct. 2024-1
Toxicol Appl Pharmacol. 2018-8-27
Histochem Cell Biol. 2025-8-15
Curr Med Sci. 2025-7-7
Liver Res. 2022-1-10
Alcohol Clin Exp Res (Hoboken). 2025-3
Pharmaceuticals (Basel). 2024-12-20
Int J Mol Sci. 2020-5-29
J Transplant. 2020-4-25
Transl Gastroenterol Hepatol. 2020-4-5
Int J Mol Sci. 2020-3-17
J Gastroenterol Hepatol. 2020-2-17